174 related articles for article (PubMed ID: 19003546)
1. Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.
He HC; Bi XC; Zheng ZW; Dai QS; Han ZD; Liang YX; Ye YK; Zeng GH; Zhu G; Zhong WD
Med Oncol; 2009; 26(3):303-8. PubMed ID: 19003546
[TBL] [Abstract][Full Text] [Related]
2. Detection of pim-1 mRNA in prostate cancer diagnosis.
He HC; Bi XC; Dai QS; Wang SS; Wei HA; Zhong WD; Liu WH; Jiang FN; Liu LS
Chin Med J (Engl); 2007 Sep; 120(17):1491-3. PubMed ID: 17908456
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.
Xu Y; Zhang T; Tang H; Zhang S; Liu M; Ren D; Niu Y
J Surg Oncol; 2005 Dec; 92(4):326-30. PubMed ID: 16299799
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.
Korbakis D; Gregorakis AK; Scorilas A
Clin Chem; 2009 May; 55(5):904-13. PubMed ID: 19299547
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
6. Expression and ERG regulation of PIM kinases in prostate cancer.
Eerola SK; Kohvakka A; Tammela TLJ; Koskinen PJ; Latonen L; Visakorpi T
Cancer Med; 2021 May; 10(10):3427-3436. PubMed ID: 33932111
[TBL] [Abstract][Full Text] [Related]
7. The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.
Ren K; Gou X; Xiao M; Wang M; Liu C; Tang Z; He W
Prostate; 2013 Sep; 73(13):1462-9. PubMed ID: 23813671
[TBL] [Abstract][Full Text] [Related]
8. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
9. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
10. [Expression of PIM-1 in prostate cancer tissue and its relationship with PSA recurrence].
Zhang CT; Xu Y; Luo F; Zhang ZH; Liu RL; Yang K; Ma BJ
Zhonghua Nan Ke Xue; 2012 Apr; 18(4):323-6. PubMed ID: 22574367
[TBL] [Abstract][Full Text] [Related]
11. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
12. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.
Lintula S; Stenman J; Bjartell A; Nordling S; Stenman UH
Prostate; 2005 Jun; 63(4):324-9. PubMed ID: 15599939
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
14. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
15. Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.
Qu Y; Zhang C; Du E; Wang A; Yang Y; Guo J; Wang A; Zhang Z; Xu Y
Med Sci Monit; 2016 Nov; 22():4254-4260. PubMed ID: 27826135
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
Ylikoski A; Pettersson K; Nurmi J; Irjala K; Karp M; Lilja H; Lövgren T; Nurmi M
Clin Chem; 2002 Aug; 48(8):1265-71. PubMed ID: 12142383
[TBL] [Abstract][Full Text] [Related]
17. Novel Insight into Differential Gene Expression and Clinical Significance of Dopamine Receptors, COMT, and IL6 in BPH and Prostate Cancer.
Akbarian F; Abolhasani M; Dadkhah F; Asadi F; Ahangari G
Curr Mol Med; 2019; 19(8):605-619. PubMed ID: 31288722
[TBL] [Abstract][Full Text] [Related]
18. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG
Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768
[TBL] [Abstract][Full Text] [Related]
19. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer.
Straub B; Müller M; Krause H; Schrader M; Miller K
Urology; 2003 Jul; 62(1):172-6. PubMed ID: 12837461
[TBL] [Abstract][Full Text] [Related]
20. Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.
Zhang CY; Zhu Y; Rui WB; Dai J; Shen ZJ
Asian J Androl; 2015; 17(1):106-10. PubMed ID: 25219913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
